Representational Image
Britain's state-run national health service will be the
first in the world to offer an injection that treats cancer to hundreds of
patients in England which could cut treatment times by up to three quarters,
reports NDTV.
Following approval from the Medicines and Healthcare
products Regulatory Agency (MHRA), NHS England said on Tuesday hundreds of
eligible patients treated with the immunotherapy, atezolizumab, were set to
have "under the skin" injection, which will free up more time for
cancer teams.
"This approval will not only allow us to deliver
convenient and faster care for our patients, but will enable our teams to treat
more patients throughout the day," Dr Alexander Martin, a consultant
oncologist at West Suffolk NHS Foundation Trust said.
NHS England said atezolizumab, also known as Tecentriq, is
usually given to patients intravenously, directly into their veins via a drip,
which could often take around 30 minutes or up to an hour for some patients
when it can be difficult to access a vein.
"It takes approximately seven minutes, compared with 30
to 60 minutes for the current method of an intravenous infusion," Marius
Scholtz, Medical Director at Roche Products Limited said.
Atezolizumab - made by Genentech, a Roche company - is an
immunotherapy drug that empowers a patient's own immune system to seek and
destroy cancerous cells. The treatment is currently offered by transfusion to
NHS patients with a range of cancers, including lung, breast, liver and
bladder.
NHS England said it expected the majority of around 3,600
patients starting the treatment of atezolizumab every year in England to switch
onto the time-saving injection.
But added that patients receiving intravenous chemotherapy
in combination with atezolizumab may remain on the transfusion.
/KN/
Editor : Shahed Mohammad Ali
Publisher : Abul Kalam Azad
Address: Times Media Bhabon (4th Floor) 387 Tejgaon Industrial Area, Dhaka-1208 l Phone : 55029832-38 l Advertisement : +8801714080378
© 2026 Samakal All Rights Reserved. Developed By Samakal Team.